System for infusing insulin to a subject to improve impaired hepatic glucose processing

• US 20050137522A1
• Filed: 12/17/2003
• Published: 06/23/2005
• Est. Priority Date: 12/17/2003
• Status: Abandoned Application

• Current Assignee: Thomas T. Aoki
• Original Assignee: Thomas T. Aoki
• Inventors: Aoki, Thomas
• Application Number:
  US10/738,899
• Publication Number:
  US 20050137522A1
• Time in Patent Office: Days
• US Class Current: 604/66
• CPC Class Codes: A61M 2205/3507 with implanted devices, e.g. external control
• CPC Class Codes: A61M 2205/3546 Range
• CPC Class Codes: A61M 2230/201 Glucose concentration
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00

Abstract

The present invention is a system for delivering insulin to a subject to improve impaired hepatic glucose processing. The system delivers a series of pulses of insulin to the subject over a period of time accompanied by ingestion of glucose in the form of a carbohydrate containing meal. The amount of insulin in each pulse, the interval between pulses and the amount of time to deliver each pulse to the subject are selected so that the hepatic processing of glucose is restored in the subject. In subjects whose hepatic glucose processing has been restored there is a subsequent fall in circulating blood glucose levels of 50 mg/dl or more directly as a result of improved hepatic glucose processing.

Claims

1. A system for infusing insulin to a subject to improve impaired hepatic glucose processing comprising the steps of:

a. a means for determining a steady baseline circulating glucose level of the subject and obtaining a subsequent circulating glucose level at least every 30 minutes, the steady baseline circulating glucose level being two consecutive circulating glucose levels about 200 milligrams per deciliter measured five minutes apart,

b. a carbohydrate containing meal,

c. a means for administering a quantity of insulin through an intravenous site until the subsequent circulating glucose level shows an improvement over the steady baseline circulating glucose level, the improvement over the steady baseline circulating glucose level being a 50 milligram per deciliter or more fall from the steady baseline circulating glucose level within two hours of administering the quantity of insulin, the subsequent circulating glucose level improvement over the steady baseline circulating glucose level being a measurement of sufficient quantity of insulin to achieve an improvement in hepatic glucose processing,

d. allowing the subject to rest at least one hour,

e. repeating steps a-d at least two times.

2. The system of claim 1, wherein the carbohydrate containing meal contains 40 to 100 grams of glucose.

3. The system of claim 1 wherein the intravenous site further comprises a needle or catheter located in the subject'"'"'s body, hand or forearm.

4. The system of claim 1, wherein the quantity of insulin contains 10 to 200 milliunits of insulin per kilogram of body weight.

5. The system of claim 1, wherein the quantity of insulin is delivered every 3 to 30 minutes.

6. The system of claim 1, wherein the quantity of insulin is delivered as a series of pulses of insulin over a period of 6 to 180 minutes.

7. The system of claim 1, wherein the means for administering a quantity of insulin is administered by an intravenous infusion device.

8. The system of claim 1, wherein the means for administering a quantity of insulin is administered by a syringe.

9. The system of claim 1, wherein the means for administering a quantity of insulin is a programmable processing unit, the programmable processing unit capable of controlling the quantity of insulin at a specified rate of delivery.

10. The system of claim 1, wherein the intravenous site is converted to a heparin or saline lock during the rest period

11. The system of claim 1, wherein the means for determining a steady baseline circulation glucose level and obtaining a subsequent circulating glucose level and the means for administering a quantity of insulin are connected by a communication link.

12. The system of claim 1, wherein the improvement in hepatic glucose processing is used to lower levels of hemoglobin A1c.

13. The system of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of diabetes related nephropathy.

14. The system of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of diabetes related retinopathy.

15. The system of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of diabetes related neuropathy.

16. The system of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of cardiovascular disease.

17. The system of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of heart disease.

18. The system of claim 1, wherein the improvement in hepatic glucose processing is used for treating wounds, promoting healing and avoiding amputations in diabetic subjects.

19. The system of claim 1, wherein the improvement in hepatic glucose processing is used to improve mental function in subjects with senile dementia.